Omega Therapeutics to Present Preclinical Data for OTX-2002 at the 2022 Annual Meeting of the American Association for Cancer Research


CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a development-stage biotechnology company pioneering the first systematic approach to using mRNA therapies as a new class of programmable epigenetic drugs in leveraging its OMEGA epigenomic programming platform, today announced that it will present preclinical data for OTX-2002, the Company’s lead drug candidate for the treatment of hepatocellular carcinoma (HCC), at the upcoming 2022 Annual Meeting of the American Association for Cancer Research (AACR), to be held at New Orleans, Louisiana, April 8-13, 2022.

“These preclinical data highlight the potential of epigenetic modulation of the c-MYC (MYC) oncogene as a promising new approach for the treatment of hepatocellular carcinoma (HCC), where overexpression of MYC is associated with aggressive disease. in up to 70% of HCC cases,” said Mahesh Karande, President and CEO of Omega Therapeutics. “Although MYC represents an attractive therapeutic target, it has historically been considered non-drug, due to the consistent failure of current modalities to inhibit MYC directly or indirectly. We look forward to sharing these data which support the potential for modulation epigenetics using our platform to systematically monitor the underlying biology of gene expression and stay on track to file an Investigational New Drug Application for OTX-2002 in the first half of 2022.”

The poster layout details for the 2022 AACR Annual Meeting are as follows:

Title: Epigenetic modulation of the MYC oncogene as a potential novel therapy for HCC
Abstract #: 2629
Date and time: Tuesday, April 12, 2022 at 09:00 by 12:30 p.m. CDT

The poster will be posted on our website at at the same time as the presentation.

About OTX-2002

OTX-2002 is a first class Omega epigenomic controller in development for the treatment of hepatocellular carcinoma (HCC). OTX-2002 is designed to modulate c-MYC (MYC) expression levels using targeted mRNA-encoded proteins to mediate epigenetic regulation while potentially overcoming MYC autoregulation. The MYC oncogene is associated with aggressive disease in approximately 70% of patients with HCC. Omega is currently evaluating OTX-2002 in Enabling Investigational New Drug (IND) studies.

About Omega Therapeutics

Omega Therapeutics, founded by Flagship Pioneering, is a development-stage biotechnology company pioneering the first systematic approach to using mRNA therapies as a new class of programmable epigenetic drugs. The company’s OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism’s life, from genesis, growth and differentiation cell to cell death. Using a suite of technologies, coupled with Omega’s systematic, rational and integrative drug design process, the OMEGA deterministic platform enables control of fundamental epigenetic processes to correct the root cause of disease by bringing back aberrant gene expression to normal range without altering native nucleic genes. acid sequences. Omega’s Modular and Programmable mRNA Epigenetic Drugs, Omega Epigenomic Controllerstarget specific epigenomic loci in isolated genomic domains, EpiZipsfrom thousands of unique, genome-wide mapped and validated DNA sequences with high specificity to sustainably adjust one or more genes to treat and cure diseases through precision genomic testing. Omega is currently advancing a wide range of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and certain single gene diseases.

For more information, visit or follow us on Twitter and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to historical facts should be considered forward-looking statements, including, without limitation, statements regarding our expectations regarding the potential of our product candidates, including our lead OEC candidate OTX-2002; and our plans to present preclinical data on OTX-2002 and file an Investigational New Drug Application for it in the first half of 2022. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, that that: the new technology upon which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtain regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new class of drugs; our limited operating history; the occurrence of material losses and the fact that we expect to continue to incur additional material losses for the foreseeable future; our need for substantial additional funding; our investments in research and development efforts that further improve the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, particularly for a new class of drugs such as epigenomic controllers; that our product candidates may be associated with serious adverse events, adverse side effects, or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in material adverse consequences; the impact of increased manufacturing demand for mRNA and LNP vaccines to treat COVID-19 on our development plans; difficulties in manufacturing the new technology upon which our OEC candidates are based; our ability to adapt to rapid and significant technological changes; our reliance on third parties to manufacture materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our dependence on a limited number of suppliers for the lipid excipients used in our product candidates; our ability to advance our product candidates into clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under “Risk Factors” in our Annual Report on Form 10-K for the period ended the 31st of December, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. Although we may choose to update these forward-looking statements at some time in the future, we disclaim any obligation to do so, even if subsequent events change our views.


Investor contacts:
Kevin Murphy/Brendan Burns
Slang Partners
[email protected]

Media contact:
Jason Braco
LifeSci Communications
[email protected]

SOURCE Omega Therapeutics


Comments are closed.